Tamar Thompson, Head Global Corporate Affairs, Alexion/Astrazeneca Rare Disease As Head of Corporate Affairs for Alexion, Mrs. Thompson oversees global communications, corporate social responsibility, diversity and inclusion, health equity, and public affairs activities, including executive level relations with global governments, patient advocacy and policy stakeholders. She directly leads a team of more than 70 employees who are responsible for external communications, internal communications, corporate social responsibility and sustainability, patient advocacy, policy, and government affairs. She advances the Company’s reputation with employees, patients, healthcare professionals, payers, government, and investors by designing and delivering strategies that effectively engage these stakeholders in the company’s mission. Tamar also serves as a key opinion leader on behalf of Alexion as well as Chairwoman of the Board for the Company’s charitable foundation. Prior to joining Alexion/AstraZeneca Rare Disease, Tamar lead Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb Company. Mrs. Thompson also served as a policy advisor and consultant for three premiere Washington DC based firms, ADVI, Kimbell & Associates and Avalere Health, where she managed a diverse portfolio of clients, including medical device, biotech, pharmaceutical, diagnostics, and specialty drug companies. Tamar serves on the board of directors for Avidity Bioscience, a clinical stage rare disease company and Catalyst Pharmaceuticals. Concurrently, she sits on the executive committee and serves as chair of the board of directors for MassBio, a state level trade association for the life science community, director emeritus for Healthy Women, a patient empowerment organization. Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress California, she has also received executive leadership certifications from Harvard University/ School of Business, Columbia University Business School and UC Berkeley.